Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Total Debt: 2011-2025

Historic Total Debt for Ligand Pharmaceuticals (LGND) over the last 6 years, with Sep 2025 value amounting to $445.5 million.

  • Ligand Pharmaceuticals' Total Debt was N/A to $445.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $445.5 million, marking a year-over-year change of. This contributed to the annual value of $76.7 million for FY2022, which is N/A change from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Total Debt of $445.5 million as of Q3 2025, which was up 480.14% from $76.8 million recorded in Q1 2023.
  • Ligand Pharmaceuticals' Total Debt's 5-year high stood at $445.5 million during Q3 2025, with a 5-year trough of $76.6 million in Q3 2022.
  • Over the past 2 years, Ligand Pharmaceuticals' median Total Debt value was $261.1 million (recorded in 2023), while the average stood at $261.1 million.